NAD+ vs NMN
Extensively Studied vs Moderate Research
synergistic Researched · 95% NMN is a direct precursor to NAD+. Combining NMN supplementation with NAD+ IV infusions or other NAD+ precursors (like NR) can provide complementary routes to NAD+ elevation. NMN handles daily maintenance while IV NAD+ provides acute high-level restoration.
Molecular Data
NAD+ NMN
Weight 663.43 Da 334.22 Da
Half-life 1-4 hours (intracellular) ~2-3 hours (oral)
Type Coenzyme Nucleotide (C11H15N2O8P)
Key Benefits
NAD+
01 Restores mitochondrial function and ATP synthesis
02 Enhances glucose and fat metabolism
03 Improves oxygen utilization and endurance
04 Activates DNA repair mechanisms
05 Supports longevity pathways via sirtuins
06 Improves mental clarity and focus
NMN
01 Increases blood and tissue NAD+ levels, counteracting age-related decline
02 Supports mitochondrial function and cellular energy production
03 Activates sirtuin pathways involved in DNA repair and longevity
04 May improve insulin sensitivity and glucose metabolism
05 Supports cardiovascular function and vascular health
06 May enhance exercise capacity and muscle endurance
07 Promotes healthy aging at the cellular level
08 Supports cognitive function and neuroprotection
Dosing Protocols
NAD+
IV: 250-1000mg; IM/SubQ: 100-500mg; Intranasal: 25-50mg; Oral precursors: 100-500mg NMN/NR / IV: 1-2x weekly; IM/SubQ: 2-3x weekly; Intranasal: 1-2x daily; Oral: daily
IV Infusion 250-1000mg 1-2x weekly
IM/SubQ 100-500mg 2-3x weekly
NMN
250-1000 mg/day / Once daily (morning)
Side Effects
NAD+
Mild flushing during IV infusion
Temporary nausea
NMN
Mild gastrointestinal discomfort (nausea, bloating, diarrhea) at higher doses
Flushing or warmth, particularly at doses above 500 mg
Mild headache during initial supplementation period
Increased energy that may affect sleep if taken too late in the day
Contraindications
IV administration requires medical supervision
Avoid alcohol during treatment
Maintain consistent dosing schedule
Known hypersensitivity to nicotinamide mononucleotide or related compounds
Active cancer (theoretical concern: NAD+ supports rapidly dividing cells; consult oncologist)
Pregnancy or breastfeeding (insufficient safety data)
Severe hepatic impairment (altered NAD+ metabolism)
Research Evidence
NAD+ NMN
Status Extensively Studied Moderate Research
References 6 studies 5 studies
Latest November 2025 April 2021
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.